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Abstract
Background: Short stature (SS) is a relatively early sign of poor health. Only in 5% of cases we can explain it
through the presence of endocrinological pathologies. Therefore, if SS is present since the first months of life,
it is necessary to investigate all systemic disorders with secondary effects on growth.
Case presentation: We report the case of a 16-months-old male infant with severe SS apparently not associated
with other clinical signs or symptoms. The patient arrived to our attention after he was hospitalized for an Echovirus
enteritis, associated to moderate neutropenia (800/mm3) and hypertransaminasemia (AST 116 U/L, ALT 88 U/L)
at the age of 13 months. SS was detected in that occasion. Since SS persisted even after the complete
resolution of enteritis symptoms, he was taken care by our unit.
Conclusions: SS appeared in the first months of life and associated with moderate neutropenia and
hypertransaminasemia led us to the diagnosis of Shwachmann-Diamond syndrome. We recommend paying
further attention to this condition during the differential diagnosis of children with severe SS.
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Background
Growth is one of the most fundamental tasks of childhood
development and short stature (SS) or growth retardation
are regarded as relatively early signs of poor health [1]. Al-
though in presence of SS pediatricians often suggest an
endocrinology evaluation, a broad spectrum of diseases
other than those due to endocrine causes may be at the
origin of this clinical sign. In fact, proportionate SS is due
to endocrinopathies only in ∼ 5% of cases. In most cases,
systemic disorders with secondary effects on growth
should be considered; among them we can remember un-
dernutrition, gastro-intestinal, cardio-pulmonary, renal
and rheumatologic diseases, cancer, immunodeficiency,
metabolic disorders, and psychosocial deprivation [2].
Consequently, the aim of the endocrinology evaluation for
a child with SS is to identify the cause of this condition
with particular attention to recognize the presence of
undetected diseases.
Case presentation
A male infant of 16 months was sent to our Pediatric
Endocrinology Centre for growth retardation reported
from the third month of life (Fig. 1).
He was born at term by vaginal delivery after an unevent-
ful pregnancy. Birth weight was 2930 g (−1.05 standard de-
viations [SD]), birth length 49 cm (−0.50 SD). Parents were
not related and had a normal stature (target height
174.5 cm). He lived with his parents in a mountain area
and had no known allergies, nor contact with infections.
No noteworthy disease was reported in family history.
Three months before our evaluation, the patient was ad-
mitted to another hospital for Echovirus enteritis, which
healed normally. SS was detected in that occasion. After
the complete resolution of enteritis symptoms, since SS
persisted, he underwent different laboratory screening test:
blood count, red blood cell indices, leucocyte differenti-
ation, erythrocyte sedimentation rate, serum creatinine,
electrolytes, calcium, phosphate, alkalin phosphatase, trans-
aminases, albumin, iron and ferritin. These exams revealed
moderate neutropenia (800/mm3) and hypertransaminase-
mia (AST 116 U/L, ALT 88 U/L) which were interpreted
as consequence of the enteral infection. Moreover,
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immunoglobulins, serological tests for celiac disease, ceru-
loplasmin, anti-nuclear antibody dosage, stool calprotectin,
fecal occult blood test, fecal eosinophils, abdominal and
heart ultrasonography were performed with normal results.
At our clinical examination, the baby appeared in good
conditions, without dysmorphic features and with normal
body proportions. While cardiothoracic, abdominal and
genital evaluations were normal, a psychomotor delay
emerged: he presented a hypotonia of lower limbs and he
was not able to walk autonomously. Poor growth was con-
firmed: bodyweight 7.8 kg (−2.55 SD), height 68 cm (−4.-
4.38 SD SD), cranial circumference 46 cm (−1.50 SD),
growth velocity 7 cm/year (−2.22 SD).
We decided to perform further examinations. We iden-
tified a slight anemia (Hb 10.1 g/dL) and confirmed a
moderate neutropenia (600/mm3) and a mild hypertransa-
minasemia (AST 91 U/L, ALT 102 U/L). Hormonal assays
(ACTH, cortisol, GH, TSH, fT4), performed to rule out
endocrinological impairment, were normal. We identified
only a low value of IGF1 (2.94 nmol/L, −5.8 DS). After
finding low fecal elastase, we performed a sweat test; its
normal values permitted to exclude the suspect of cystic
fibrosis. Celiac disease was also ruled out again. Spine and
pelvis X-ray did not show focal lesions, but highlighted
coxa valga, ossification delay and oval vertebrae (Fig. 2).
Bone age exam showed a severe ossification delay.
In consideration of poor growth, psychomotor delay,
anemia, neutropenia, hypertransaminasemia and low fecal
elastase, we suspected a Shwachmann-Diamond syndrome
(SDS). Consequently, a complete pancreatic assay was per-
formed with the identification of low fecal chymotripsyn
and low plasmatic levels of amilase and lipase. Subse-
quently, genetic analysis for SBDS gene was performed
and resulted in compound heterozygosis for c.183-
184TA > CT + 258 + 2 T > C, confirming the clinical
suspect.
Discussion and conclusions
The SDS is a rare autosomal recessive disorder, described
for the first time in 1964, whose estimated incidence is of
1 in 77,000 people [3]. The SBDS gene, located on long
arm of chromosome 7 (7q.11) is mutated in 90% of
patients. The protein encoded by SBDS gene appears to
be involved in RNA metabolism or ribosome function,
affecting exocrine pancreas, bone, cartilage and bone mar-
row cells development, but its function is still unknown.
Consequently, the clinical manifestations are related to
exocrine pancreatic insufficiency, with malabsorption and
malnutrition; to bone marrow failure, with neutropenia,
anemia, thrombocytopenia or pancytopenia; to skeletal
anomalies, with abnormal development of growth plates
and metaphyses, delayed bone age as well as progressive
deformities and pathological fractures. All these symptoms
are associated with SS and mild cognitive impairment.
Classically SDS presents neutropenia associated with
diarrhea [4]; in our case these typical features were
Fig. 1 in figure the growth chart of our patients is represented (Who, 2006)
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misinterpreted as viral enteritis. Furthermore, on this
occasion hypertransaminasemia and failure to thrive were
also explained as consequence of this acute infection. In
fact, it is known that acute viral gastroenteritis may cause
elevation of AST and ALT level [5] and are associated with
weight loss and growth retardation [6]. Similarly the asso-
ciation between neutropenia and gastroenteritis is known
and some authors suggest that mild neutropenia accom-
panying diarrhea does not require further evaluation, un-
less it persists or is associated with other factors such as
sepsis [7]. Therefore, only the subsequent evaluation after
the acute infectious episode suggested a more severe dis-
order. In particular, three symptoms were decisive for our
diagnosis: the presence of neutropenia; the persistent
hypertransaminasemia; and finally growth failure.
Since the most common causes of neutropenia are
acquired and due to viral infection, drugs and auto-
immune etiology [8], the persistence of neutropenia in
our patient despite the absence of infection made us as-
sume that it was due to a chronic situation. Moreover,
the association between neutropenia and anemia was
suggestive of pancytopenia. The pancytopenia with an
important neutropenia was the clinical sign that led to
the final diagnostic hypothesis. In fact SDS, along with
Fanconi syndrome, dyskeratosis congenita and amega-
karyocytic thrombocytopenia, is among the main con-
genital causes of pancytopenia. In patients with SDS the
cytopenias are secondary to marrow failure and neutro-
penia is the most common hematological abnormality,
being reported in 88% to 100% of patients. It can be
either intermittent or persistent, occurring with recur-
rent infections. Therefore, the viral enteritis presented
by our patient was probably due to his neutropenia.
Among other haematological signs, normochromic nor-
mocytic anemia with low reticulocytes occurs in up to
80% of SDS patients and it is often asymptomatic [9].
Another hall-mark of SDS is exocrine pancreatic dys-
function with or without nutrient maldigestion. Pancreatic
dysfunction is usually diagnosed within the first six
months of life and in 90% of patients during the first year.
Clinical manifestations range widely from severe dysfunc-
tion with significant nutrient malabsorption, steatorrhea,
and resultant failure to thrive, to completely asymptom-
atic. Many patients with SDS spontaneously improve with
age; several studies, based on evidence of normal fat
absorption in up to 50% of patients, have shown that
enzyme supplementation can be stopped by 4 years
[10]. The typical clinical findings of exocrine pancre-
atic dysfunction can be documented with low serum
concentrations of the digestive pancreatic enzymes,
low levels of fecal elastase and with supportive features
such as abnormal fecal fat balance study of a 72-h stool
collection, pancreatic lipomatosis at ultrasonography, re-
duced levels of fat soluble vitamins, reduced pancreatic
enzyme secretion following quantitative pancreatic stimu-
lation testing with cholecystokinin and secretin. In our pa-
tient, persistent failure to thrive, associated with diarrhea,
induced us to measure fecal elastase; its low level enabled
us to suspect exocrine pancreatic dysfunction. On the
contrary, his abdominal ultrasonography was completely
normal and did not highlight pancreatic alterations nor
hepatomegaly. Nevertheless his transaminase levels in-
creased over time and were essential for the diagnosis.
Hepatomegaly and liver dysfunction with elevated serum
Fig. 2 in figure the spine and pelvis X-ray in laterocervical a and in anteroposterior b projections is represented
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aminotransferase concentration, in fact, are seen in up to
75% of patients with SDS, most often in infants and young
children, and tend to resolve with age [11].
Although our patient had no dysmorphic features and
did not present evident body disproportions, probably
also due to his young age, we suspected slight lower
limbs alterations. His delay in walking finally suggested
us to perform a spine and pelvis X-ray. These exam
evidenced a coxa valga, an ossification delay and some
oval vertebrae. These alterations, though not specific for
SDS, are part of the typical variety of bone anomalies in
SDS. Typical feature of SDS is metaphyseal chondrodys-
plasia. The radiographic findings may be subtle in early
childhood such as mild rib shortening and distal rib flar-
ing or cupping, and become more apparent as the child
grows, particularly in the lower limbs. The metaphyseal
changes lead to asymmetrical metaphyseal growth and
deformity. Moreover, generalized disturbance in bone
metabolism, as well as delayed appearance of secondary
ossification centers, has been shown in SDS; these symp-
toms cause bone age delay and abnormal bone turnover,
with decreased activity of both osteoclasts and osteo-
blasts [12, 13]. In conformity with these data, the bone
age of the patient showed a severe ossification delay.
Growth failure is a common feature of SDS and is
described in most cases since the first months of life,
even if its causes are not fully understood. It seems
only to a small extent caused by skeletal abnormal-
ities, chronic malnutrition, pancreatic insufficiency
and recurrent infections with only partial response to
pancreatic extracts [14]. An associated growth hormone
deficiency (GHD) is rarely reported; in our patient we did
not investigated a GHD, but we identified low level of
IGF1 that, however, may be also correlated to his malnu-
trition. It is known that nutrition plays a crucial role in
growth during early infancy, and a poor nutritional status
may be also a cause of growth retardation [15]. Anyhow,
SS and poor growth rate can be the first manifestations of
undetected diseases in children. It is indeed estimated that
about 20% of children with a height less than 2 SD below
the mean and around 50% of the children with a height
less than 3 SD below the mean have a pathological reason
for their small size [16]. Poor growth can be caused by a
great diversity of congenital or acquired conditions, not
only endocrinological, such as cystic fibrosis or celiac dis-
ease, which, as mentioned above, we have excluded in our
patient. In order to recognize these conditions, some
laboratory exams are needed, but there is no consensus
about which test should be performed [17]. Hematological
parameters are suggested by all authors as first-step evalu-
ation, because the association between anemia and SS is a
nonspecific marker of a growth related disorder; other
tests as transaminases assay are instead under debate.
Whereas some authors recommend to investigate the
transaminases in presence of SS with unknown eti-
ology [17], other authors do not include this param-
eter in routine investigations, because they consider
that short children with liver disorder are usually not
asymptomatic [1, 18]. We identified the cause of our
patient’s SS only through the association between
growth retardation, neutropenia and elevated transam-
inases’ levels in absence of specific symptoms. In fact,
as above mentioned, persistent hypertransaminasemia
is one of clinical signs of SDS [19]. Consequently, we
suggest to always evaluate transaminases in children
with SS appeared in the first months of life.
In this case, clinical history (growth retardation, psy-
chomotor delay assessment), together with silent familiar
history, no-specific physical examination, first level la-
boratory testing abnormalities (anemia, neutropenia,
hypertransaminasemia), led to second level investiga-
tions on blood and on fecal samples and subsequently
genetic analysis, which confirmed SDS diagnosis. Even if
a drawback in our diagnostic process may be the ex-
tended variety of tests performed, we believe that they
allowed to properly focus on the most specific abnor-
malities, without invasive methods and with efficient
and rapid insight of the diagnosis.
In conclusion, we recommend physicians to routinely
measure transaminases levels in infants presenting severe
SS in the first months of life. Moreover, when SS is associ-
ated with moderate neutropenia and hypertransaminase-
mia, it is mandatory to hypothesize a SDS and to proceed
with further exams, such as the analysis of fecal elastase, a
complete pancreatic assay and the genetic of SBDS gene,
to confirm the clinical suspect.
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